Kennewick, WA – July 8, 2026 – Vivos Inc. (OTCQB: RDGL) is pleased to announce that its abstract titled “Postoperative Precision Radionuclide Brachytherapy for Incomplete Tumor Resection” has been accepted by the American College of Veterinary Surgeons (ACVS) for presentation at the upcoming ACVS Surgical Summit in October 2026.
This acceptance follows the successful completion of patient enrollment in Vivos’ 20-patient prospective clinical study evaluating IsoPet® Postoperative Precision Radionuclide Therapy™ (PRnT) for the treatment of incomplete histologic margins after tumor resection in client-owned veterinary patients.
The study demonstrated strong preliminary results, including:
- Successful treatment delivery in all 20 cases with no procedural or device-related complications.
- No Grade 3 or higher acute adverse events.
- Only one patient experienced mild, transient Grade 1–2 erythema and edema that resolved without intervention.
- Median follow-up of 4 months, with no local regrowth identified in 12 cases to date and successful retreatment in eight recurrent cases.
“IsoPet® continues to show excellent feasibility and a favorable safety profile as a convenient, single-procedure postoperative option for managing microscopic residual disease,” said Brad Weeks, President of Vivos Inc. “We are pleased that the ACVS has accepted our abstract and look forward to sharing these encouraging early clinical findings with leading veterinary surgeons at the October Summit. This presentation represents a significant step forward in validating IsoPet® as a valuable new tool in veterinary oncology.”
The ACVS Surgical Summit is one of the premier gatherings for veterinary surgeons, providing an ideal platform to present IsoPet®’s innovative approach to precision radionuclide therapy. The company anticipates this visibility will further accelerate clinical adoption and commercial momentum for IsoPet® across certified veterinary clinics.
Vivos Inc. remains committed to advancing its clinical research program and generating additional peer-reviewed data to support broader use of IsoPet® Postoperative PRnT in the management of challenging tumors in companion animals.
About Vivos Inc.
Vivos Inc. is developing advanced Yttrium-90 based brachytherapy devices for the treatment of tumors in both animals (IsoPet®) and humans (RadioGel®). The Company is committed to delivering safer, more effective, and accessible cancer therapies through Precision Radionuclide Therapy™.
Forward-Looking Statements
This announcement contains forward-looking statements within the meaning of applicable securities laws. Actual results may differ materially from those expressed or implied due to various risks and uncertainties.
Contact:
Mike Korenko, ScD
CEO, Vivos Inc.
mkorenko@radiogel.com
Brad Weeks
President, Vivos Inc.
brad.weeks@vivosinc.com
Follow Vivos Inc. on X (Twitter): @VivosIncUSA
Learn more about RadioGel® and IsoPet® at www.VivosInc.com
